MARKET

TCON

TCON

Tracon Pharmaceu
OTCMQB
0.650
+0.028
+4.47%
Opening 09:39 07/17 EDT
OPEN
0.650
PREV CLOSE
0.622
HIGH
0.650
LOW
0.650
VOLUME
2.50K
TURNOVER
1.62K
52 WEEK HIGH
14.75
52 WEEK LOW
0.601
MARKET CAP
1.74M
P/E (TTM)
0.999
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TCON last week (0708-0712)?
Weekly Report · 2d ago
Weekly Report: what happened at TCON last week (0701-0705)?
Weekly Report · 07/08 09:41
Tracon Pharmaceuticals Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 07/01 17:53
HC Wainwright & Co. Downgrades TRACON Pharma to Neutral
Benzinga · 07/01 17:43
TRACON PHARMACEUTICALS, INC. <TCON.PK>: H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY
Reuters · 07/01 15:44
TRACON ends development of envafolimab, exploring strategic options
Seeking Alpha · 07/01 14:33
Tracon Pharmaceuticals Scraps Development of Sarcoma Drug, Seeks to Explore Strategic Alternatives
Dow Jones · 07/01 13:40
TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF ENVASARC TRIAL AND WILL EXPLORE STRATEGIC ALTERNATIVES LEVERAGING ITS IN-HOUSE PRODUCT DEVELOPMENT PLATFORM
Reuters · 07/01 13:00
More
About TCON
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Webull offers TRACON Pharmaceuticals Inc stock information, including OTCMQB: TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCON stock methods without spending real money on the virtual paper trading platform.